277 related articles for article (PubMed ID: 27695345)
41. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
Ruiz Salas V; Alegre M; Garcés JR; Puig L
Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
[TBL] [Abstract][Full Text] [Related]
42. Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature.
Proietti I; Filippi L; Tolino E; Bernardini N; Svara F; Trovato F; Di Cristofano C; Petrozza V; Bagni O; Vizzaccaro A; Skroza N; Potenza C
Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001904
[No Abstract] [Full Text] [Related]
43. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors.
Bossi P; Ascierto PA; Basset-Seguin N; Dreno B; Dummer R; Hauschild A; Mohr P; Kaufmann R; Pellacani G; Puig S; Moreno-Ramírez D; Robert C; Stratigos A; Gutzmer R; Queirolo P; Quaglino P; Peris K
Crit Rev Oncol Hematol; 2023 Sep; 189():104066. PubMed ID: 37442495
[TBL] [Abstract][Full Text] [Related]
44. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
Yin VT; Esmaeli B
Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Hedgehog Pathway Inhibition on Nevoid Basal Cell Carcinoma Syndrome Fibroblasts and Basal Cell Carcinoma-Associated Fibroblasts: Are Vismodegib and Sonidegib Useful to Target Cancer-Prone Fibroblasts?
Eibenschutz L; Caputo S; Camera E; Carbone A; Silipo V; Migliano E; Aurizi C; Cota C; Frascione P; Bellei B
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831015
[TBL] [Abstract][Full Text] [Related]
46. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
[TBL] [Abstract][Full Text] [Related]
47. Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer.
Wilken R; Criscito M; Pavlick AC; Stevenson ML; Carucci JA
Facial Plast Surg; 2020 Apr; 36(2):200-210. PubMed ID: 32413929
[TBL] [Abstract][Full Text] [Related]
48. Experience with sonidegib in patients with advanced basal cell carcinoma: case reports.
Puig S; Serra-Guillén C; Pérez-Pastor G; Martínez-Domenech Á; Fernández-de-Misa Cabrera R
Drugs Context; 2022; 11():. PubMed ID: 35677182
[TBL] [Abstract][Full Text] [Related]
49. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
Chen L; Silapunt S; Migden MR
Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494
[TBL] [Abstract][Full Text] [Related]
50. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
51. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
[TBL] [Abstract][Full Text] [Related]
52. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
53. Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib.
Yoon J; Apicelli AJ; Pavlopoulos TV
JAAD Case Rep; 2018 Jan; 4(1):10-12. PubMed ID: 29387745
[No Abstract] [Full Text] [Related]
54. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
55. Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence.
Tay EY; Teoh YL; Yeo MS
Dermatol Ther (Heidelb); 2019 Mar; 9(1):33-49. PubMed ID: 30539424
[TBL] [Abstract][Full Text] [Related]
56. L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma
Zhu M; Wang H; Wang C; Fang Y; Zhu T; Zhao W; Dong X; Zhang X
Front Pharmacol; 2019; 10():89. PubMed ID: 30846937
[TBL] [Abstract][Full Text] [Related]
57. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.
Pietrobono S; Stecca B
Cells; 2018 Dec; 7(12):. PubMed ID: 30558232
[TBL] [Abstract][Full Text] [Related]
58. PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation.
Chow RY; Jeon US; Levee TM; Kaur G; Cedeno DP; Doan LT; Atwood SX
Front Oncol; 2021; 11():668247. PubMed ID: 34268113
[TBL] [Abstract][Full Text] [Related]
59. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma.
Lear JT; Dummer R; Guminski A
Oncotarget; 2021 Dec; 12(26):2531-2540. PubMed ID: 34966484
[TBL] [Abstract][Full Text] [Related]
60. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
